Merrill keeps Onyx at neutral

Onyx Pharmaceuticals, Inc. was maintained at neutral by Merrill Lynch analyst Eric Ende on news that The European Medicines Agency issued a positive opinion recommending approval of Nexavar, as well as competitor Sutent, for kidney cancer earlier than expected. Merrill increased its loss-per-share estimates to $1.93 from $1.75 in 2006, and to a $0.22 loss per share from a $0.09 loss per share in 2007. Shares of the Emeryville, Calif., biopharmaceutical company were down 10 cents, or 0.43%, at $23.35 on volume of 625,790 shares versus the three-month running average of 642,241 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.